Lupin Issued US FDA Form 483 with Two Observations at Ankleshwar Site

announced that the US FDA completed an inspection at its Ankleshwar, India manufacturing facility from March 2 to March 7, 2026, resulting in a Form 483 listing two observations . This standard notice highlights procedural issues noted by inspectors but does not constitute a final determination on compliance with current good manufacturing practices (cGMP) . The company plans to respond within the required 15-day window, underscoring its commitment to regulatory standards. Q3 FY26 results showed consolidated net profit of ₹1,175.6 crore (up 37.5% YoY) on revenue of ₹7,167.5 crore (up 24.3% YoY), despite sequential declines . Investors will monitor Lupin's remediation efforts for potential impacts on US operations. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.